291 related articles for article (PubMed ID: 18954143)
1. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
Landgraf KE; Pilling C; Falke JJ
Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
[TBL] [Abstract][Full Text] [Related]
2. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3).
Pilling C; Landgraf KE; Falke JJ
Biochemistry; 2011 Nov; 50(45):9845-56. PubMed ID: 21932773
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.
Dannemann N; Hart JR; Ueno L; Vogt PK
Int J Cancer; 2010 Jul; 127(1):239-44. PubMed ID: 19876913
[TBL] [Abstract][Full Text] [Related]
4. GRP1 pleckstrin homology domain: activation parameters and novel search mechanism for rare target lipid.
Corbin JA; Dirkx RA; Falke JJ
Biochemistry; 2004 Dec; 43(51):16161-73. PubMed ID: 15610010
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
6. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
[TBL] [Abstract][Full Text] [Related]
7. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
[TBL] [Abstract][Full Text] [Related]
8. AKT1(E17K) in human solid tumours.
Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
[TBL] [Abstract][Full Text] [Related]
9. Membrane activity of the phospholipase C-delta1 pleckstrin homology (PH) domain.
Flesch FM; Yu JW; Lemmon MA; Burger KN
Biochem J; 2005 Jul; 389(Pt 2):435-41. PubMed ID: 15755258
[TBL] [Abstract][Full Text] [Related]
10. Membrane docking geometry of GRP1 PH domain bound to a target lipid bilayer: an EPR site-directed spin-labeling and relaxation study.
Chen HC; Ziemba BP; Landgraf KE; Corbin JA; Falke JJ
PLoS One; 2012; 7(3):e33640. PubMed ID: 22479423
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML; Lien EC; Toker A
Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
Kim MS; Jeong EG; Yoo NJ; Lee SH
Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
[TBL] [Abstract][Full Text] [Related]
13. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of membrane binding of the GRP1 PH domain.
Lai CL; Srivastava A; Pilling C; Chase AR; Falke JJ; Voth GA
J Mol Biol; 2013 Sep; 425(17):3073-90. PubMed ID: 23747485
[TBL] [Abstract][Full Text] [Related]
15. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of specific membrane targeting by C2 domains: localized pools of target lipids enhance Ca2+ affinity.
Corbin JA; Evans JH; Landgraf KE; Falke JJ
Biochemistry; 2007 Apr; 46(14):4322-36. PubMed ID: 17367165
[TBL] [Abstract][Full Text] [Related]
17. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
[TBL] [Abstract][Full Text] [Related]
19. A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.
Deyle KM; Farrow B; Qiao Hee Y; Work J; Wong M; Lai B; Umeda A; Millward SW; Nag A; Das S; Heath JR
Nat Chem; 2015 May; 7(5):455-62. PubMed ID: 25901825
[TBL] [Abstract][Full Text] [Related]
20. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
